The proliferation of non-neoplastic
gradually following stimulation with PHA. None of the other protooncogenes tested was expressed in PBMC. Addition of the protein synthesis inhibitor cycloheximide, before the addition of PHA to cultures, abolished the PHA-induced accumulation of mRNAs for c-myb, N-ras, and TFR, but not of mRNAs for c-fos, c-myc, IL2, and MMR. These data indicate that c-fos, c-myc, IL2, and JL2R belong to a group of genes expressed early, whereas c-myb, N-ras, and TFR belong to a group of genes expressed later in PHA-activated PBMC, and that the products of the c-fos and c-myc protooncogenes are not required for expression of IL2 or 12R genes. Addition of purified IL2 augmented the expression of the later-expressed genes c-myb, p53, N-ras, and TFR in PHA-stimulated cultures of PBMC, as well as of the early genes c-myc and JUL2R, but not of c-fos and IL2, thus suggesting that PHA and IL2 stimulate the expression of overlapping, but nonidentical, sets of genes in PBMC.
Human peripheral blood lymphocytes have been employed extensively as a model system for investigating the regulation of the initial stages of cellular proliferation and entry into the cell cycle. When freshly isolated from whole blood, these cells are a good example of "G0"-phase cells (1, 2) . Recent evidence (reviewed in refs. 3 and 4) indicates that upon stimulation of resting (Go-phase) lymphocytes with the mitogenic lectin phytohemagglutinin (PHA), T cells enter the G1 phase of the cell cycle, where they produce interleukin 2 (IL2, formerly "T-cell growth factor") and express receptors for this growth factor. The interaction of IL2 with its cellular receptor (IL2R) on activated T cells results in the expression of transferrin receptors (TFR). Binding of serum transferrin to its receptor in late G1 phase of the cell cycle is then required for T cells to undergo the G1-+S-phase transition.
Other factors, including insulin and insulin-like growth factors, do not appear to be necessary, at least for short-term growth of T cells.
Besides growth factors and their receptors, proteins encoded by protooncogenes are candidates for regulators of lymphocyte proliferation. Protooncogenes represent the cellular counterparts of transforming DNA sequences initially isolated from acutely transforming retroviruses. These cellular genes constitute part of the normal genomes of eukaryotic species as disparate as human and yeast (5) . Though cellular oncogenes have been studied primarily for their role in carcinogenesis, their high degree of evolutionary conservation and the fact that many are expressed in developing embryonic tissues have suggested that protooncogenes may play an important role in the regulation of normal growth and differentiation (6) .
Recently, we and others have observed that expression of the c-myc protooncogene is transiently induced in human peripheral blood mononuclear cells (PBMC) after stimulation with PHA (7) (8) (9) . How c-myc expression relates to other critical events oflymphocyte activation remains obscure, and little information is available on the expression of other protooncogenes in normal lymphocytes. For this reason, we used cDNAs homologous to 21 different protooncogenes as hybridization probes to screen for their expression at the RNA level in cultures of human PBMC stimulated with PHA. By comparing the regulation of expression of these protooncogenes to the accumulation ofmRNA for IL2, IL2R, TFR, and histone H3, we have assigned c-fos, c-myc, IL2, and IL2R to a class of early-response genes and assigned c-myb, N-ras, and TFR to a class of genes expressed later in PHA-activated PBMC.
MATERIALS AND METHODS PBMC were purified from whole blood and cultured at 2 x 106 per ml in RPMI 1640 medium containing 10% heatinactivated fetal bovine serum and PHA-P (Difco), purified recombinant human IL2 [lot LP-230B; produced in Escherichia coli (67) and a gift of Cetus (Emeryville, CA)], cycloheximide (Sigma), or various combinations of these reagents as described previously (9) . At various times, PBMC were recovered from cultures and total cellular RNA was isolated by a guanidinium isothiocyanate procedure (10) with CsCl gradient centrifugation (11 (9, 12, 13 experiments wherein PBMC were cultured for various times with PHA before isolation of total cellular RNA and determination of the time course of expression of various genes by standard RNA-blotting techniques. Because levels of ribosomal RNA increase in lymphocytes after stimulation with PHA, we compared equivalent amounts of RNA (10 ,.g per lane) rather than comparing RNA from equal numbers of cells. As shown in Fig. 1 , and as reported previously by us and others (7) (8) (9) , elevations in the levels of c-myc mRNA were detectable within 15-30 min and reached maximal levels (20-to 40-fold increase) within 1-2 hr. Similar results were obtained with c-fos (40-fold increase) except that levels of c-fos mRNA returned quickly to baseline, whereas c-myc mRNA remained at elevated levels until 24-48 hr. The decline in the levels of c-myc mRNA coincides roughly with the entry of PHA-activated PBMC into the S phase of the cell cycle, as determined by expression of histone H3 sequences (30-fold increase; Fig. 1 ).
In several experiments we observed a biphasic response of c-myc expression, with an initial peak in the accumulation of c-myc mRNA occurring at 1-2 hr and a second, lower peak at 24 hr ( Fig. 1 ). This may reflect two rounds of c-myc expression in PHA-stimulated T cells, the first occurring very soon after binding ofmitogenic lectin to resting lymphocytes, and the second occurring later when IL2 interacts with its receptor on activated T cells. Previously, we have shown that IL2 can induce expression of the c-myc protooncogene in activated (Gl-phase) lymphocytes, in that: (I) purified IL2 augments and anti-Tac antibody (anti-IL2R) diminishes levels of c-myc mRNA in PHA-stimulated PBMC at 24 hr, after they have expressed receptors for IL2, but not at 3 hr, before IL2R are expressed (9); and (it) IL2 induces rapid accumulation of c-myc mRNA in cloned, IL2-responsive T cells (12) .
Hybridization of RNA blots with a 32P-labeled plasmid DNA encoding the IL2R gene (IL2R) (23) revealed bands corresponding to lengths of 3.5 kb and 1.5 kb (only the 3.5-kb band is shown). Increases in the accumulation of IL2R mRNAs were detectable within 2-6 hr after stimulation ofPBMC with PHA and peaked at 14-24 hr at levels 60-to 80-fold higher than in unstimulated PBMC. Similarly, levels of IL2 mRNA became detectable at 2-6 hr and maximal at 6-14 hr (15-fold increase). In contrast to IL2 and IL2R mRNA, the accumulation of a 4.9-kb mRNA for TFR was not detectable until [6] [7] [8] [9] [10] [11] [12] [13] [14] hr and generally reached maximal levels (10-fold increase) at 14-48 hr. These latter findings are consistent with a previous report (41) that the interaction of IL2 with its receptor on activated T lymphocytes is a necessary step for the expression of TFR. Unlike IL2R and TFR, human insulin receptor mRNA was detectable in unstimulated PBMC and increased only slightly (4-fold) following stimulation with PHA.
Investigation of c-ras expression, using cDNA probes specific for N-ras (35) , Ha-ras (33) , and Ki-ras (34) revealed that only N-ras ( Fig. 1) was expressed in PBMC. Stimulation with PHA increased the accumulation of a 4.0-kb N-ras mRNA from low but detectable levels in resting cells to levels 10-to 15-fold above baseline within hr. The increased expression of N-ras preceded the onset of histone H3 mRNA accumulation and followed the expression of c-myc, c-fos, IL2 , and ML2R, suggesting that increased expression of N-ras (like the increase in TFR expression) occurs late in the G, phase of the cell cycle.
Because the products of c-fos and c-myc are nucleoproteins (42, 43), we tested PBMC for expression of two other nucleoprotein-encoding protooncogenes, c-myb (44) and p53 (30, 45) . Using a human cDNA probe for c-myb, we detected increased accumulation of a 3.8-kb mRNA at 6-14 hr in PHA-stimulated PBMC that reached maximal levels (50-fold increase) within 48-72 hr (Fig. 1) . Expression of a 2.5-kb p53 mRNA followed a similar time course (Fig. 1) Of the other oncogenes screened-including abl (68), B-lym (24), erbA (14) , erbB (14) , ets (15) , fes (16) , fms (17) , fps (19) , mos (26) , N-myc (28), pim-(31), raf (32), rel (36) , sis (37) , src (38) , T-lym (25) , and yes (40)-only abl, ets, and yes were expressed at easily detectable levels in our RNA blot assay (Fig. 1) . Hybridization of RNA blots with 32p_ labeled probes revealed major bands at 5.3 kb, 2.0 kb, and 2.3 kb, respectively, in unstimulated PBMC (Fig. 1) . Levels of c-abl, c-ets, and c-yes mRNA increased gradually following stimulation of PBMC with PHA.
Effect of Cycloheximide on Protooncogene Expression Induced by PHA in PBMC. As a first step toward investigating the possibility that some of the genes expressed following PHA stimulation of PBMC may depend on the prior expression of other genes such as c-fos and c-myc, we employed the protein synthesis inhibitor cycloheximide. Addition of cycloheximide (15 ,ug/ml) at the initiation of PBMC cultures did not impair the accumulation of mature transcripts of c-fos, c-myc, IL2R, or 1L2 but, rather, elevated the levels of these mRNAs in both the presence and the absence of mitogen (Fig. 2) . This finding suggests the presence in PBMC of a labile protein (or proteins) that normally represses transcription of these genes and/or prevents processing or stabilization of their transcripts (46) . In contrast, cycloheximide abrogated the PHA-induced increase in the later-appearing mRNAs for c-myb, N-ras, and TFR, showing that protein synthesis is necessary for the activation of these genes. The effect of cycloheximide on p53 mRNA accumulation was equivocal. Cycloheximide augmented levels of p53 mRNA in resting PBMC but reduced levels of p53 mRNA in PHAstimulated cells (data not shown).
The data in Fig. 2 indicate that the c-fos and c-myc gene products are not required for activation of genes for IL2 or its Effects of Purified IL2 on Protooncogene Expression in PBMC. Because the experiments using cycloheximide suggested that the accumulation of mRNAs for c-myc, N-ras, and TFR was dependent on protein synthesis (Fig. 2) , we wondered whether IL2 production was necessary for the expression of these later genes in PHA-stimulated PBMC. To investigate this possibility, cultures of PBMC were stimulated with a suboptimal concentration of either PHA (0.01%, vol/vol), IL2 (50 units/ml), or both or were not stimulated, and RNA was isolated after 12-24 hr for blot analysis. Suboptimal concentrations of PHA induce IL2R expression but not enough IL2 production to achieve saturation of IL2R. In this way, addition of exogenous IL2 produces a further increase in IL2-inducible gene expression.
As shown in Fig. 3 , IL2 augmented the levels of mRNAs for c-myc, c-myb, p53, N-ras, IL2R, and TFR in PHAactivated PBMC. In contrast, IL2 did not increase levels of mRNAs for c-fos, IL2, or PGK. Though c-fos mRNA had presumably declined to undetectable levels by 12 hr after stimulation with PHA (the time of this analysis; Fig. 3 ), the time-course data in Fig. 1 (vol/vol) dilution (lanes 3), or cycloheximide plus PHA-P (lanes 4). Cycloheximide was always added 0.5 hr before PHA. PBMC were recovered from cultures after either 1 hr (c-fos and c-myc) or 24 hr (all others), and total RNA was analyzed for relative levels of various mRNAs by RNA blot assay (9, 12, 13 (9, 12, 13 (47) (48) (49) .
Presumably, the cells chiefly responsible for the observed increases in protooncogene mRNAs are T lymphocytes, since T cells constitute 75-80% of PBMC, with s5% B cells (9) , and since PHA preferentially stimulates T cells (50) . In this regard, we have observed that expression of c-fos, c-myc, c-myb, and p53 can be induced in cloned T cells (unpublished data). Also, preliminary reports from two other laboratories indicate that c-fos, c-myc, and c-myb are expressed in T-cell lines (51, 52) . However, we have not excluded the possibility that non-T cells contribute to the levels of protooncogene expression that we measured, nor have we ascertained whether the expression of any of these protooncogenes is limited to a subpopulation of T cells. Further studies are needed to determine whether the PHAinduced alterations in the levels of mRNAs seen here are paralleled by similar changes in the levels of proteins encoded by these protooncogenes.
Given the time course of expression of various genes in PHA-stimulated PBMC (Fig. 1) and the effects of cycloheximide on the accumulation of their mRNAs (Fig. 2) , we can classify c-fos, c-myc, IL2R, and IL2 as early-response genes expressed during T-lymphocyte mitogenesis and c-myb, N-ras, and TFR as late-response genes. These designations of early and late genes, as well as such terms as "competence" and "progression" genes (53) , should be viewed with caution, however, because we and others (9, 12, 13, 54) have observed previously that IL2 can up-regulate the levels of c-myc and of IL2R mRNAs. Thus, expression of at least some of the early-response genes (namely, c-myc and IL2R) appears to be stimulated both at the onset of PHA-stimulated cultures, when PHA binds to T cells, and later, when IL2 binds to its cellular receptor on activated (Gl-phase) T cells. Accordingly, some genes may belong to both the early and the late classes of genes.
Expression of other genes besides c-myc and IL2R may be induced in PBMC both when mitogenic lectin binds to resting (Go) T cells and again later when IL2 interacts with activated (Gl) T cells. The data in Fig. 3 , for example, show that exogenous IL2 augments the accumulation of mRNAs for c-myb, p53, N-ras, and TFR, in addition to mRNAs for c-myc and IL2R. Thus, like the expression of c-myc and IL2R, expression of c-myb, p53, N-ras, and TFR in PHA-activated PBMC is, at least in part, regulated by IL2. Whether IL2 binding to its cellular receptor is the sole signal responsible for the accumulation of these later-appearing mRNAs in cultures of PHA-stimulated PBMC (see Fig. 1 ) or whether both PHA and IL2 independently induce expression of these genes cannot be determined from these data alone. For instance, addition of suboptimal concentrations of PHA alone to PBMC cultures did induce some accumulation of mRNAs for c-myb, p53, N-ras, and TFR, but this may be explained by production of small amounts of endogenous IL2 induced by PHA in these cultures. Conversely, though cycloheximide (see Fig. 2 ) impaired the PHA-induced accumulation of mRNAs for c-myb, N-ras, and TFR (results with p53 were equivocal), the inhibition was not always complete, thus raising the possibility that PHA, independent of its ability to induce IL2 production, contributes to the increases in the levels of these later-appearing mRNAs. Nonetheless, our data showing that IL2 up-regulates the expression of c-myc, IL2R, c-myb, p53, N-ras, and TFR, but not c-fos and IL2, indicates that PHA and IL2 regulate the expression of overlapping but nonidentical sets of genes in PBMC. Given that signal transduction mediated by receptors for mitogenic lectins and for IL2 appears to occur, at least in part Our observations regarding c-myc expression, as well as those of other investigators (7-9, 12, 46, 54) , differ from a recent report by Thompson et al. (56) that levels of c-myc mRNA are invariant throughout the cell cycle. These investigators separated exponentially growing lymphoid and fibroblast cell lines into subpopulations based on cell volume arguing that cell size increases with progression through the cell cycle, and observed little variation in the levels of c-myc mRNA among these subpopulations. Similar to our findings, the data of Thompson et al. (56) showed that levels of c-myc mRNA were lower in G0-phase cells than in cycling populations, but, unlike us, these investigators failed to detect a fall in c-myc mRNA levels in S, G2, and M phases of the cell cycle following G1 phase. This discrepancy may reflect differences between primary cultures of PBMC that undergo only one or two rounds of cell division following stimulation with PHA (57) and exponentially growing cells. In this regard, Lachman et al. (58) have used cell-volume fractionation techniques to show that high levels of c-myc mRNA are present in all phases of the cell cycle in exponentially growing cells of the murine erythroleukemic line MEL. However, upon chemical induction of differentiation of MEL cells, during which these cells undergo four to five divisions before ceasing to proliferate, accumulation of c-myc mRNA became limited predominantly to the G1 phase of the cell cycle (58) . Thus, in cells undergoing multiple, successive divisions, it may be that the temporal regulation of c-myc mRNA accumulation is altered, compared to cells that undergo only a limited number of cell divisions.
The biological functions of protooncogenes in lymphocytes are a matter for speculation. Because of technical difficulties of introducing genes into lymphocytes and of microinjecting these suspension cells, functional studies of lymphocytes have lagged behind work with other cell types, such as fibroblasts. Similarities between lymphocytes and fibroblasts with regard to protooncogene expression and cell cycle progression are striking, with, for example, PHA and PDGF (platelet-derived growth factor), respectively, inducing a similar time course of expression of c-fos, c-myc, p53, and c-ras genes (59) (60) (61) . Moreover, fibroblasts appear to require sequentially three growth factors for S-phase entry-PDGF, epidermal growth factor (EGF), and insulin-like growth factor I (IGF-I)-whereas T cells also require sequentially three factors for progression to the S phase of the cell cycleantigen or mitogenic lectin (and possibly interleukin 1), IL2, and transferrin (3, 4, 41, 53) . These parallels between lymphocytes and fibroblasts suggest commonality in the role of protooncogenes in the regulation of normal mammalian cell growth. Consequently, functional studies of protooncogenes in fibroblasts and other cell types may provide clues to the roles these genes play in lymphocytes. For example, microinjection studies in fibroblasts have shown that both c-myc and p53 genes can induce competence for growth factors (presumably EGF and IGF-I) present in platelet-poor plasma (62, 63) . By analogy, perhaps c-myc and p53 genes, though not necessary for IL2R expression (see Fig. 2 ), are important for competence for IL2-induced growth. In addition, microinjection studies in fibroblasts have also provided evidence that c-ras genes can induce the Gj-3S-phase transition (64, 65) , raising the possibility that N-ras may regulate critical events in late G1 phase of the cell cycle in T cells. With regard to c-yes, this gene encodes a protein with extensive amino acid homology to the product of the c-src gene, pp6osrc (40) . Previous studies have suggested a role for pp6Osrc in the control of receptor signal transduction mediated through phosphatidylinositol turnover (reviewed in ref. 66 ). Because Immunology: Reed et al. 3Proc . Natl. Acad. Sci. USA 83 (1986) both mitogenic lectins and IL2 induce increased phosphatidylinositol metabolism in T lymphocytes (55) , one could speculate that c-yes might play a role in signal transduction mediated via receptors for mitogenic lectins and for IL2.
Finally, because most growth-factor receptors have tyrosine kinase activity, c-abl, which encodes a membrane-associated tyrosine kinase (5) , is a candidate, as is c-yes (5, 40) , for the postulated tyrosine kinase molecule associated with receptors for antigen and for IL2 in T cells. Despite these speculations, specific evidence concerning the normal functions of protooncogenes in lymphocytes is needed before confident generalizations can be made and the altered role of these genes in neoplastic cells better understood. 
